Abstract
Background and Aims : LOF mutation on ASGR1 is associated with lower non-HDL cholesterol and reduced incidence of CVD. The beneficial effect of ASGR1 deficiency goes beyond the achieved reduction in non-HDL cholesterol levels a call for lipid unrelated effects. This project aims to investigate the molecular mechanism of ASGR1 to impact dyslipidemia and CVD outcome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
